New perspectives in the therapy of chronic hepatitis B

Gut

Volumn 61, Issue SUPPL. 1, 2012, Pages

  Lampertico, Pietro ^a   Liaw, Yun Fan ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; INTERLEUKIN 28B; LAMIVUDINE; LAMIVUDINE PLUS PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOREGULATION; LIVER CIRRHOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; DRUG MONITORING; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; PHOSPHONIC ACIDS; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 84860325201     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302085     Document Type: Review

References (46)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
3. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012. In press.
4. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;46:399-401.
5. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009;41:1100-4.
6. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
7. Martin MP, Qi Y, Goedert JJ, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010;202:1749-53.
8. Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon alpha-2a therapy. Antivir Ther 2011;16:629-37.
9. Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012;142:513-20.e1. Published Online First 19 November 2011.
10. Wu X, Xin Z, Zhu X, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012;93:297-300.
11. Lampertico P, Viganò M, Cheroni C, et al. Genetic variation in IL28B polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated with interferon alfa. Hepatology 2010;52(suppl):442A.
12. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-9.
13. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010;52:475-7.
14. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55:1121-31.
15. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;54: E1-9.
16. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44.
17. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
18. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7.
19. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all HBeAg-positive patients. Hepatology 2011;53:1054-5.
20. Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa- 2a in hepatitis B e antigen-positive patients. Hepatol Int. Published Online First: 24 June 2011. doi:10.1007/s12072-011-9280-0
21. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61.
22. Rijckborst V, Hansen B, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. Published Online First: 13 January 2012. doi:10.1016/j.jhep.2011.12.007
23. Lampertico P, Viganò M, Di Costanzo GG, et al. A response guided approach to peg-interferon alfa-2a at weeks 12 and 24 improves response rates in HBeAg-negative, genotype D chronic hepatitis B patients. Hepatology 2011;54:1021A.
24. Brunetto MR, Marcellin P, Cherubini B, et al. response to peginterferon alfa-2a in HBeAg negative CHB: baseline and on-treatment kinetics of HBsAg serum levels vary according to HBV genotype. Hepatology 2011;54:1059A.
25. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha 2a. Antivir Ther 2009;14:1183-8.
26. Chang TT, Lai CL, Kew YS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
27. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.
28. Manns M, Akarca US, Chang TT, et al. Low rates of nucleos(t)ide- associated adverse events in the long-term experience with entecavir. J Hepatol 2010;52:S393.
29. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43.
30. Marcellin P, Buti M, Gane EJ, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011;54(Suppl 1):1011Ae12A. Abstract 1375.
31. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-73.
32. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF and Entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
33. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized open-label study. Hepatology 2011;54:91-100.
34. Sogni P, Carrieri MP, Fontaine H, et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues: implications for clinical management. Antivir Ther 2012;17:395-400.
35. Chotiyaputta W, Peterson C, Ditah FA, et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011;54:12-18.
36. Buti M, Morillas RM, Prieto M, et al. A viral load reduction >3 log at 12 week of Entecavir treatment correlated with HBe seroconversion in HBeag positive patients. Results from a real-life setting study (the ORIENTE study). Hepatology 2010;52(Suppl 1). Abstract 409.
37. Ridruejo E, Adrovar R, Cocozella D, et al. Effectiveness of entecavir in chronic hepatitis B NUC-naïve patients in routine clinical practice. Int J Clin Pract 2011;65:866-70.
38. Carey I, Nguyen H-L, Joe D, et al. De-novo antiviral therapy with nucleos(t)ide analogues in 'real-life' patients with chronic hepatitis B infection: comparison of virological responses between lamivudine+adefovir, entecavir vs. tenofovir therapy. Hepatology 2011;54(Suppl 1):1022A. Abstract 1396.
39. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-51.
40. Lampertico P, Vigano M, Soffredini R, et al. Entecavir monotherapy for nuc-naive chronic hepatitis B patients from field practice: high efficacy and favorable safety profile over 3 years. Hepatology 2011;54 (Suppl 1):1043A. Abstract 1436.
41. Seto WK, Lai CL, Fung J, et al. Outcome of 4-year treatment of entecavir for treatment-naïve chronic hepatitis B. J Hepatol 2011;54:S301.
42. Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011;106:1264-71.
43. Lampertico P, Soffredini R, Viganò M, et al. 2 year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice. Hepatology 2011;54(Suppl 1):1041A. Abstract 1433.
44. Lok AS, Trinh H, Carosi G, et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naïve patients with chronic hepatitis B (CHB): the BE-LOW study. Hepatology 2011;54(Suppl 1):471A. Abstract 471A.
45. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-10.
46. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.